HOSPITAL • ST. LOUIS **BJC** HealthCare[™]

Childre

Background

- Asthma is a significant health issue for children, with more than 700,000 pediatric patients visiting emergency departments each year
- The 2024 Global Initiative for Asthma guidelines a National Heart, Lung, and Blood Institute guidelin use of rapid acting inhaled bronchodilators, syster controlled oxygen supplementation for and exacerbations.
- Quality improvement projects aimed at standardizin scoring and the improvement of timely administ through order sets have been associated with re department (ED) length of stays (LOS) and admiss

Objectives

This study is evaluating the ED's choice of syster frequency of adjunctive medications administered, albuterol dose compliance, and order set usage/comp

Methods

Review Board at Institutional Southern The Edwardsville approved this retrospective study.

Figure 1. Patient Encounters with Albuterol Admini

975 patient encounters including patients a less than 21 years old with a primary asthi diagnosis that received albuterol in the ED were admitted to St. Louis Children's Hosp between April 1, 2022, and May 31, 2023



ICU, Intensive Care Unit: CABS, Children's Asthma/Bronchiolitis Scores

Compliance of Corticosteroid and Albuterol Treatment in the Emergency Department

Trent Bueckman, PharmD/MBA Candidate and Kimberly P. Mills, PharmD, BCPPS

St. Louis Children's Hospital, St. Louis, MO

along with the 2020 nes recommend the mic corticosteroids, or acute asthma
ing asthma severity stration of albuterol educed emergency sion rates.
mic corticosteroids, corticosteroid and pliance.
Illinois University
aged ma and bital 3
ients excluded due to 3S documented in the ED
ents excluded for not ving select asthma therapies
nts excluded for use of terbutaline

Table 1. Patient Demographics					
Characteristic		N=607			
Male sex, n (%)		359 (59.1)			
Race, n (%)*					
Black		407 (67.1)			
White		199 (32.8)			
Other		5 (0.8)			
Unknown		1 (0.2)			
Median age, years (IQR)		4 (2-7)			
Median weight, kg (IQR)		18 (14.1-30.9)			
*Patients could be included in ≥ 1 category	I	```			
Table 2. Patient Encounte	er Charact	eristics			
Characteristic		N=683			
Chief Complaint, n (%)*					
Respiratory Distress		386 (56.5	5)		
Asthma Exacerbation		183 (26.8	3)		
Cough		63 (9.2)	63 (9.2)		
Shortness of Breath		37 (5.4)	37 (5.4)		
Other		71 (8.6)			
Median ED LOS, hours (IQR)		5.3 (5-7)			
Patient Disposition					
Floor		465 (68.1)			
ICU		218 (31.9)			
Median ICU LOS, days (IQR)		1.4 (1-2)			
Median Hospital LOS, days (IQR) 1.8 (1-3)					
*Patients could be included in ≥ 1 category ED, Emergency Department; ICU, Intensive Care Unit; IQR, Interquartile Range; LOS, Length of Stay					
Table 3. Patient Disposition Comparison					
Characteristic in the ED,	Floor	ICU	P-value		
n (%)	(n=465)	(n=218)			
Exacerbation severity			<0.0001		
$ Mild (CABS \leq 3) \\ Madarata (CABS 4.6) $	154(33.1)	28(12.8)	<0.0001		
Noderale (CABS 4-6) Severe (CABS > 7)	235(50.5) 76(163)	7/(33.2)	0.515		
Corticosteroid administered	205 (85)	181 (83)	0.52		
Devamethasone*	233(590)	63 (34 8)	<0.02		
Prednisolone/Prednisone*	134 (33.9)	63 (34.8)	0.836		
Methylprednisolone*	28 (7.1)	57 (30.4)	<0.0001		
Albuterol/ipratropium	452 (97.2)	202 (92.7)	0.006		
1-hour continuous albuterol	133 (28.6)	172 (78.9)	<0.0001		
Intermittent albuterol	152 (32.7)	61 (28)	0.216		
Magnesium	135 (29)	165 (75.7)	<0.0001		
Epinephrine IM	4 (0.9)	27 (12.4)	<0.0001		

*Relative to patient encounters with corticosteroid administration CABs, Children's Asthma/Bronchiolitis Scores; ED, Emergency Department; IM, Intramuscular

Results

Table 4. Patient Disposition and Medication Guideline Compliance

Characteristic, n (%)

Corticosteroid compliance* Selection based on CABS First dose compliance (mg/kg)

Albuterol dose compliance** Albuterol/ipratropium

1-hour continuous albuterol

*Relative to patient encounters with corticosteroid administration **Relative to patient encounters with specified albuterol administration CABS, Children's Asthma/Bronchiolitis Scores

Table 5. Characteristics Associated with Albuterol Dose Non-compliance

Characteristic, n (%)

Any albuterol override Any albuterol ordered outside of an order set

Figure 2. Median Time Between Select Asthma Therapies in the Emergency Department



- set were more likely to be non-compliant with the asthma guidelines.



Floor (n=465)	ICU (n=218)	P-value
345 (87.3)	126 (69.6)	<0.0001
374 (94.7)	160 (88.4)	0.007
375 (83)	157 (77.7)	0.112
120 (90.2)	163 (94.8)	0.128

All albuterol doses compliant (n=535)	Any non-compliant albuterol (n=133)	P-value
173 (32.2)	61 (45.9)	0.001
205 (38.3)	70 (52.6)	0.011

Conclusion

Methylprednisolone was administered more often in patient encounters resulting in ICU admission. Dexamethasone was more commonly administered in patient encounters resulting in floor admission; however, it was the first corticosteroid administered in one-third of patients encounters resulting in ICU admission. Corticosteroid selection and dose were more likely to be compliant in patient encounters resulting in floor vs ICU admission, which may have resulted from provider comfortability with dexamethasone over methylprednisolone. • Patient encounters with any albuterol override or order source outside of an order

Education on avoiding dexamethasone in severe exacerbations, optimizing methylprednisolone dosing, opportunities to improve CABS documentation, and increased order set utilization are needed to improve guideline compliance.

All authors: Nothing to disclose